查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575508

Esomeprazole市場：按產品類型、應用、最終用戶、分銷管道、年齡層分類 - 全球預測 2025-2030

Esomeprazole Market by Product Type (Dosage Strength, Over The Counter, Prescription-Based), Application (Gastroesophageal Reflux Disease, Peptic Ulcer, Zollinger-Ellison Syndrome), End User, Distribution Channel, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Esomeprazole市值為17.3億美元，預計2024年將達到18.3億美元，複合年成長率為5.92%，到2030年將達到25.9億美元。

Esomeprazole是質子幫浦阻斷劑，主要用於治療胃食道逆流（GERD）、柔林格症候群和其他與胃酸相關的疾病。 360iResearch的市場研究分析師表示，KEYWORD的需求在於其透過減少胃酸來緩解症狀和修復食道損傷的功效。其應用範圍涵蓋醫院、診所和家庭護理機構，最終用途尤其適用於需要長期管理酸相關病症的患者。影響埃索Esomeprazole市場的關鍵成長要素包括由於飲食和生活方式的改變而導致的胃食道逆流患者病率上升、認知和診斷率的提高以及全球醫療基礎設施的持續擴張。此外，非處方藥的趨勢正在增加可近性並促進市場成長。醫療保健支出不斷增加的新興市場存在潛在機會，例如胃腸道疾病盛行率不斷增加的亞太地區。製劑技術和給藥系統的創新，例如延遲釋放製劑和複合製劑，代表了改善生物有效性和患者依從性的有前途的研究和開發途徑。然而，市場成長面臨嚴格監管、潛在副作用以及來自學名藥和替代療法的激烈競爭等挑戰。此外，發展中地區的價格敏感度和專利到期也是主要威脅。鼓勵希望利用這些機會的公司優先考慮藥物安全研究、有效的聯合治療和非傳統市場的開拓。您還可以透過專注於病患教育工作來提高您的市場佔有率。創新重點包括開發個人化醫療方法和探索新型藥物輸送系統以改善治療結果。目前，Esomeprazole市場受到需求和技術進步的推動，競爭環境良好，機會充足，業務成長前景廣闊。透過利用這些見解，公司可以調整其策略以克服現有挑戰並最佳化其成長潛力。

主要市場統計
基準年[2023] 17.3億美元
預測年份 [2024] 18.3億美元
預測年份 [2030] 25.9億美元
複合年成長率（%） 5.92%

市場動態：揭示快速發展的Esomeprazole市場的關鍵市場洞察

供需的動態交互作用正在改變Esomeprazole市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球胃腸道疾病盛行率上升
    • 擴大醫療基礎設施以改善胃腸道治療的可近性
    • 支持Esomeprazole在醫療環境中使用的有利政府政策和報銷制度
  • 市場限制因素
    • 與Esomeprazole相關的監管和合規問題
  • 市場機會
    • 製藥公司之間的策略合作和夥伴關係，以創新基於Esomeprazole的治療方法
    • 持續的研發工作導致先進的Esomeprazole製劑的推出
  • 市場挑戰
    • Esomeprazole生產原料缺乏

波特的五力：駕馭Esomeprazole市場的策略工具

波特的五力架構是了解Esomeprazole市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Esomeprazole市場的外部影響

外部宏觀環境因素在塑造Esomeprazole市場表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解Esomeprazole市場的競爭狀況

對Esomeprazole市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣Esomeprazole市場供應商的績效評估

FPNV定位矩陣是評估Esomeprazole市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了Esomeprazole市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，Esomeprazole市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球胃腸道疾病的發生率正在上升
      • 擴大醫療基礎設施改善胃腸道治療的可近性
      • 有利的政府政策和報銷制度支持Esomeprazole在醫療機構中的使用
    • 抑制因素
      • 與Esomeprazole相關的監管和合規問題
    • 機會
      • 製藥公司之間的策略合作和夥伴關係，以創新Esomeprazole為基礎的治療方法
      • 不斷的研究和開發努力推出了先進的Esomeprazole
    • 任務
      • Esomeprazole生產原料缺乏
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Esomeprazole市場：依產品類型

  • 劑量強度
    • 高劑量
    • 低劑量
    • 中等劑量
  • 店面銷售(OTC)
    • 膠囊
    • 其他格式
    • 暫停
    • 藥片
  • 根據處方箋
    • 膠囊
    • 注射
    • 暫停
    • 藥片

第7章Esomeprazole市場：依應用分類

  • 胃食道逆流症（GERD）
    • 急性治療
    • 維持治療
  • 消化性潰瘍
    • 十二指腸潰瘍
    • 胃潰瘍
  • 柔林格症候群

第 8 章Esomeprazole市場：依最終用戶分類

  • 診所
    • 普通科診所
    • 專科診所
  • 家庭護理設置
  • 醫院
    • 私立醫院
    • 公立醫院

第9章Esomeprazole市場：按分銷管道

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章Esomeprazole市場：依年齡層

  • 成人用
  • 老年病
  • 小兒科

第11章美洲Esomeprazole市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區Esomeprazole市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲Esomeprazole市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C6291879C

The Esomeprazole Market was valued at USD 1.73 billion in 2023, expected to reach USD 1.83 billion in 2024, and is projected to grow at a CAGR of 5.92%, to USD 2.59 billion by 2030.

Esomeprazole, a proton pump inhibitor, is primarily used to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related disorders. As the market research analyst at 360iResearch, the necessity of esomeprazole lies in its effectiveness in reducing stomach acid, thereby providing symptom relief and healing esophageal damage. Its application spans across hospitals, clinics, and homecare settings, with end-use notably being patients requiring long-term management of acid-related conditions. Key growth factors influencing the esomeprazole market include the rising prevalence of GERD due to dietary and lifestyle changes, increasing awareness and diagnosis rates, and the ongoing expansion of healthcare infrastructure globally. Furthermore, the trend towards over-the-counter availability facilitates easier access, propelling market growth. Potential opportunities reside in emerging markets with increasing healthcare expenditure like Asia-Pacific, where the prevalence of gastrointestinal disorders is rising. Innovations in formulation technology and delivery systems present a promising avenue for R&D, offering enhanced bioavailability and patient compliance, such as delayed-release or co-formulation products. On the other hand, market growth faces challenges from stringent regulations, potential side effects, and the intense competition from generics and alternative therapies. Additionally, price sensitivity in developing regions and patent expirations pose significant threats. For businesses aiming to capitalize on these opportunities, prioritizing research in drug safety, effective combination therapies, and exploring non-traditional markets are recommended. Emphasizing patient education initiatives can also enhance market presence. Innovation focuses could include the development of personalized medicine approaches and exploring novel drug delivery systems for improved therapeutic outcomes. The esomeprazole market currently exhibits a competitive yet opportunity-rich environment, driven by both necessity and technological advancement, offering robust prospects for business growth. By leveraging these insights, companies can align strategies to navigate existing challenges and optimize growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 1.73 billion
Estimated Year [2024] USD 1.83 billion
Forecast Year [2030] USD 2.59 billion
CAGR (%) 5.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Esomeprazole Market

The Esomeprazole Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of gastrointestinal disorders globally
    • Expanding healthcare infrastructure improving access to gastrointestinal therapies
    • Favorable government policies and reimbursement schemes supporting the use of esomeprazole in medical practice
  • Market Restraints
    • Regulatory and compliance issues associated with esomeprazole
  • Market Opportunities
    • Strategic collaborations and partnerships among pharmaceutical companies to innovate esomeprazole-based treatments
    • Ongoing research and development efforts leading to the introduction of advanced esomeprazole formulations
  • Market Challenges
    • Raw material shortages for the production of esomeprazole

Porter's Five Forces: A Strategic Tool for Navigating the Esomeprazole Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Esomeprazole Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Esomeprazole Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Esomeprazole Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Esomeprazole Market

A detailed market share analysis in the Esomeprazole Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Esomeprazole Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Esomeprazole Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Esomeprazole Market

A strategic analysis of the Esomeprazole Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Esomeprazole Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Cipla, Dr. Reddy's Laboratories, Eli Lilly and Company, Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Merck & Co., Mylan, Novartis, Pfizer, Sandoz, Sanofi, Sun Pharmaceutical, Takeda Pharmaceutical Company, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Esomeprazole Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Dosage Strength, Over The Counter (OTC), and Prescription-Based. The Dosage Strength is further studied across High Dosage, Low Dosage, and Medium Dosage. The Over The Counter (OTC) is further studied across Capsules, Other Forms, Suspensions, and Tablets. The Prescription-Based is further studied across Capsules, Injection, Suspensions, and Tablets.
  • Based on Application, market is studied across Gastroesophageal Reflux Disease (GERD), Peptic Ulcer, and Zollinger-Ellison Syndrome. The Gastroesophageal Reflux Disease (GERD) is further studied across Acute Treatment and Maintenance Treatment. The Peptic Ulcer is further studied across Duodenal Ulcer and Gastric Ulcer.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of gastrointestinal disorders globally
      • 5.1.1.2. Expanding healthcare infrastructure improving access to gastrointestinal therapies
      • 5.1.1.3. Favorable government policies and reimbursement schemes supporting the use of esomeprazole in medical practice
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory and compliance issues associated with esomeprazole
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations and partnerships among pharmaceutical companies to innovate esomeprazole-based treatments
      • 5.1.3.2. Ongoing research and development efforts leading to the introduction of advanced esomeprazole formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Raw material shortages for the production of esomeprazole
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Esomeprazole Market, by Product Type

  • 6.1. Introduction
  • 6.2. Dosage Strength
    • 6.2.1. High Dosage
    • 6.2.2. Low Dosage
    • 6.2.3. Medium Dosage
  • 6.3. Over The Counter (OTC)
    • 6.3.1. Capsules
    • 6.3.2. Other Forms
    • 6.3.3. Suspensions
    • 6.3.4. Tablets
  • 6.4. Prescription-Based
    • 6.4.1. Capsules
    • 6.4.2. Injection
    • 6.4.3. Suspensions
    • 6.4.4. Tablets

7. Esomeprazole Market, by Application

  • 7.1. Introduction
  • 7.2. Gastroesophageal Reflux Disease (GERD)
    • 7.2.1. Acute Treatment
    • 7.2.2. Maintenance Treatment
  • 7.3. Peptic Ulcer
    • 7.3.1. Duodenal Ulcer
    • 7.3.2. Gastric Ulcer
  • 7.4. Zollinger-Ellison Syndrome

8. Esomeprazole Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
    • 8.2.1. General Clinics
    • 8.2.2. Specialty Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals
    • 8.4.1. Private Hospitals
    • 8.4.2. Public Hospitals

9. Esomeprazole Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Stores
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Retail Pharmacies

10. Esomeprazole Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Esomeprazole Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Esomeprazole Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Esomeprazole Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amneal Pharmaceuticals
  • 3. AstraZeneca
  • 4. Boehringer Ingelheim
  • 5. Cipla
  • 6. Dr. Reddy's Laboratories
  • 7. Eli Lilly and Company
  • 8. Glenmark Pharmaceuticals
  • 9. Lupin Pharmaceuticals
  • 10. Merck & Co.
  • 11. Mylan
  • 12. Novartis
  • 13. Pfizer
  • 14. Sandoz
  • 15. Sanofi
  • 16. Sun Pharmaceutical
  • 17. Takeda Pharmaceutical Company
  • 18. Teva Pharmaceuticals
  • 19. Torrent Pharmaceuticals
  • 20. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. ESOMEPRAZOLE MARKET RESEARCH PROCESS
  • FIGURE 2. ESOMEPRAZOLE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ESOMEPRAZOLE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ESOMEPRAZOLE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ESOMEPRAZOLE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ESOMEPRAZOLE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ESOMEPRAZOLE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ESOMEPRAZOLE MARKET DYNAMICS
  • TABLE 7. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HIGH DOSAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY LOW DOSAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY MEDIUM DOSAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY OTHER FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY MAINTENANCE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DUODENAL ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GASTRIC ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ZOLLINGER-ELLISON SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 334. FRANCE ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 343. FRANCE ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 344. FRANCE ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. FRANCE ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 346. GERMANY ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. GERMANY ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 348. GERMANY ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 355. GERMANY ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 356. GERMANY ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 357. GERMANY ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 358. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 360. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 361. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 362. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 363. ISRAEL ESOMEPRAZOLE MA